|Bid||253.51 x 900|
|Ask||253.88 x 1100|
|Day's range||252.56 - 257.95|
|52-week range||179.37 - 301.34|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||74.15|
|Earnings date||26 Jan 2022 - 31 Jan 2022|
|Forward dividend & yield||1.68 (0.66%)|
|Ex-dividend date||09 Nov 2021|
|1y target est||265.83|
It is hard to get excited after looking at ResMed's (NYSE:RMD) recent performance, when its stock has declined 13% over...
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
Desney Tan Desney Tan, ResMed board director John Hernandez, ResMed board director John Hernandez, ResMed board director Tan is vice president and managing director of Microsoft’s Health and Life Science R&D Hernandez is Google’s head of clinical research, health economics, and outcomes researchBoth leaders’ digital health experience at world-leading tech firms can help oversee ResMed’s strategy to improve 250 million lives in 2025ResMed’s board increases from eight to ten directors SAN DIEGO, N